IDH1 and acute myeloid leukemia: Most therapies against aberrant metabolism in AML LSC have been directed against IDH1/2 and BCL2; however, a growing number are also targeting other processes such as OXPHOS, Ferroptosis, etc. We will limit our discussion to BCL2 and IDH1/2 inhibitors as the gathered evidence is strongest here (Fig. 4C).